We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-15.77%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$584M
AUM Growth
-$130M
Cap. Flow
-$2.08M
Cap. Flow %
-0.36%
Top 10 Hldgs %
80.9%
Holding
33
New
4
Increased
7
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$30M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$5.74M
3
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$3.98M
4
BPMC
Blueprint Medicines
BPMC
+$3.26M
5
AERI
Aerie Pharmaceuticals
AERI
+$2.29M

Top Sells

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$22.6M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$12.6M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$8.38M
4
MRUS
Merus
MRUS
+$7.25M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$6.27M

Sector Composition

Rank Sector Weight
1 Healthcare 73.42%
2 Technology 10.28%
3 Communication Services 9.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
26
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.5M 0.26%
+35,900
New +$1.52M
ZGNX
27
DELISTED
Zogenix, Inc.
ZGNX
$1.43M 0.24%
+35,700
New +$1.65M
COGT icon
28
Cogent Biosciences
COGT
$7.14B
$682K 0.12%
118,360
– –
GKOS icon
29
Glaukos
GKOS
$10.1B
– –
-300,000
Closed -$22.6M
LKFT
30
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
– –
-97,481
Closed -$12.6M
MRUS
31
DELISTED
Merus
MRUS
– –
-495,016
Closed -$7.25M
NBRV
32
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-13,786
Closed -$8.38M
1
2

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return

Novo Holdings A/S's Q3 2019 Portfolio in Review

As of Q3 2019, Novo Holdings A/S held 33 positions worth $584M, down 18% from $714M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Novo Holdings A/S's Q3 2019 filing shows 4 new, 7 increased, 2 reduced and 4 closed positions. Its largest new stake was Mirum Pharmaceuticals: 2,445,147 shares worth $24.6M. The largest sale was Glaukos, an estimated $22.6M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 80% a quarter earlier, followed by Technology and Communication Services.

  • Novo Holdings A/S's largest Q3 2019 buy was Mirum Pharmaceuticals: 2,445,147 shares worth $24.6M.
  • Novo Holdings A/S added most to Protagonist Therapeutics in Q3 2019, an estimated $5.74M increase.
  • Novo Holdings A/S's biggest Q3 2019 reduction was Corvus Pharmaceuticals, cutting an estimated $6.27M.
  • Novo Holdings A/S fully exited Glaukos in Q3 2019, selling an estimated $22.6M.
  • Novo Holdings A/S's ten largest holdings make up 81% of its $584M portfolio in Q3 2019.
  • Novo Holdings A/S opened 4 new positions and closed 4 in Q3 2019.
  • Novo Holdings A/S's portfolio value fell 18% quarter-over-quarter to $584M.

Based on Novo Holdings A/S's 13F filing for Q3 2019, filed 14 Nov 2019.